Claritas Pharmaceuticals, Inc. (CLAZF)

0.0001 0.0000 (0.00%) At close: 03:22PM EDT

Claritas Pharmaceuticals, Inc.

4040 Civic Center Drive
Suite 200
San Rafael, CA 94903
United States

https://claritaspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Robert Farrell J.D.	Chairman, CEO & President	300k	N/A	N/A
Ms. Victoria Diana Rudman	Interim CFO, Treasurer & Secretary	75k	N/A	1968
Mr. Seth Yakatan	Co-Founder	22.5k	N/A	1970
Dr. Stuart L. Silverman	Co-Chair of Scientific Advisory Board and Vice President of Medical Affairs	N/A	N/A	1947
Dr. Sari Prutchi-Sagiv Ph.D.	Chief Scientific Officer	146k	N/A	N/A
Dr. Moshe Yeshurun M.D.	Chief Medical Officer	86k	N/A	N/A
Dr. Amos Rosenthal Ph.D.	Head of Chemistry	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.

Corporate Governance

Claritas Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.